Skip to Main content Skip to Navigation
Preprints, Working Papers, ...

Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model

Abstract : Abstract Impaired type I interferons (IFNs) production or signaling have been associated with severe COVID-19, further promoting the evaluation of recombinant type I IFNs as therapeutics against SARS-CoV-2 infection. In the Syrian hamster model, we show that intranasal administration of IFN-α starting one day pre-infection or one day post-infection limited weight loss and decreased viral lung titers. By contrast, intranasal administration of IFN-α starting at the onset of symptoms three days post-infection had no impact on the clinical course of SARS-CoV-2 infection. Our results provide evidence that early type I IFN treatments are beneficial, while late interventions are ineffective, although not associated with signs of enhanced disease. One Sentence Summary The timing of type I interferon treatment is a critical determinant of its efficacy against SARS-CoV-2 infection.
Complete list of metadata

https://hal-anses.archives-ouvertes.fr/anses-03387992
Contributor : Sophie Marchal-Mauer Connect in order to contact the contributor
Submitted on : Wednesday, October 20, 2021 - 10:34:31 AM
Last modification on : Saturday, November 20, 2021 - 3:44:59 AM

File

2021.02.09.430458v1.full.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Pierre Bessière, Marine Wasniewski, Evelyne Picard-Meyer, Alexandre Servat, Thomas Figueroa, et al.. Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. 2021. ⟨anses-03387992⟩

Share

Metrics

Record views

62

Files downloads

33